MDxHealth SA (NASDAQ:MDXH) Given Average Rating of “Moderate Buy” by Brokerages

MDxHealth SA (NASDAQ:MDXH) has been assigned an average recommendation of “Moderate Buy” from the five brokerages that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $7.75.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MDxHealth in a research note on Friday, March 27th.

MDxHealth Price Performance

Shares of MDxHealth stock opened at $1.99 on Thursday. MDxHealth has a fifty-two week low of $1.70 and a fifty-two week high of $5.33. The firm has a market cap of $98.51 million, a P/E ratio of -2.97 and a beta of 1.60. The firm has a 50 day simple moving average of $2.58 and a 200 day simple moving average of $3.31.

MDxHealth (NASDAQ:MDXH) last announced its quarterly earnings data on Friday, February 27th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.04). MDxHealth had a negative net margin of 31.07% and a negative return on equity of 1,078.01%. The business had revenue of $29.55 million during the quarter, compared to the consensus estimate of $26.05 million. On average, sell-side analysts expect that MDxHealth will post -0.41 EPS for the current year.

Hedge Funds Weigh In On MDxHealth

A number of hedge funds and other institutional investors have recently bought and sold shares of MDXH. Intesa Sanpaolo Wealth Management bought a new position in MDxHealth in the fourth quarter valued at approximately $36,000. Lido Advisors LLC bought a new position in MDxHealth in the third quarter valued at approximately $48,000. GSA Capital Partners LLP bought a new position in MDxHealth in the third quarter valued at approximately $48,000. Squarepoint Ops LLC bought a new position in MDxHealth in the fourth quarter valued at approximately $51,000. Finally, Jefferies Financial Group Inc. bought a new position in MDxHealth in the third quarter valued at approximately $53,000.

About MDxHealth

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.